Literature DB >> 20608900

The diuretic bumetanide decreases autistic behaviour in five infants treated during 3 months with no side effects.

Eric Lemonnier1, Yehezkel Ben-Ari.   

Abstract

UNLABELLED: The inhibitory transmitter GABA has been suggested to play an important role in infantile autistic syndrome (IAS), and extensive investigations suggest that excitatory actions of GABA in neurological disorders are because of a persistent increase of [Cl(-) ](I) . AIMS: To test the effects of the chloride co-transporter NKCC1 diuretic compound Bumetanide that reduces [Cl(-) ](I) on IAS.
METHODS: Bumetanide was administered daily (1mg daily) during a 3-month period and clinical and biological tests made. We used 5 standard IAS severity tests - Childhood Autism Rating Scale, Aberrant Behaviour Checklist, Clinical Global Impressions; Repetitive and Restrictive Behaviour and the Regulation Disorder Evaluation Grid.
RESULTS: We report a significant improvement in IAS with no side effects.
CONCLUSION: Bumetanide decreases autistic behaviour with no side effects suggesting that diuretic agents may exert beneficial effects on IAS and that alterations of the actions of GABA may be efficient in IAS treatment calling for large scale randomized trials.
© 2010 The Author(s)/Acta Paediatrica © 2010 Foundation Acta Paediatrica.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20608900     DOI: 10.1111/j.1651-2227.2010.01933.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  51 in total

1.  Is it safe to use a diuretic to treat seizures early in development ?

Authors:  Y Ben-Ari; R Tyzio
Journal:  Epilepsy Curr       Date:  2011-11       Impact factor: 7.500

Review 2.  Unifying Views of Autism Spectrum Disorders: A Consideration of Autoregulatory Feedback Loops.

Authors:  Caitlin Mullins; Gord Fishell; Richard W Tsien
Journal:  Neuron       Date:  2016-03-16       Impact factor: 17.173

Review 3.  Neurobiology of autism gene products: towards pathogenesis and drug targets.

Authors:  Kristel T E Kleijer; Michael J Schmeisser; Dilja D Krueger; Tobias M Boeckers; Peter Scheiffele; Thomas Bourgeron; Nils Brose; J Peter H Burbach
Journal:  Psychopharmacology (Berl)       Date:  2014-01-14       Impact factor: 4.530

Review 4.  Revisiting the excitation/inhibition imbalance hypothesis of ASD through a clinical lens.

Authors:  Russell G Port; Lindsay M Oberman; Timothy Pl Roberts
Journal:  Br J Radiol       Date:  2019-06-11       Impact factor: 3.039

5.  The effect of bumetanide treatment on the sensory behaviours of a young girl with Asperger syndrome.

Authors:  Marine Grandgeorge; Eric Lemonnier; Céline Degrez; Nelle Jallot
Journal:  BMJ Case Rep       Date:  2014-01-31

6.  Reversing excitatory GABAAR signaling restores synaptic plasticity and memory in a mouse model of Down syndrome.

Authors:  Gabriele Deidda; Martina Parrini; Shovan Naskar; Ignacio F Bozarth; Andrea Contestabile; Laura Cancedda
Journal:  Nat Med       Date:  2015-03-16       Impact factor: 53.440

7.  Social Communication is an Emerging Target for Pharmacotherapy in Autism Spectrum Disorder - A Review of the Literature on Potential Agents.

Authors:  Danielle A Baribeau; Evdokia Anagnostou
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2014-02

Review 8.  Pharmacological Modulation of GABA Function in Autism Spectrum Disorders: A Systematic Review of Human Studies.

Authors:  Natascia Brondino; Laura Fusar-Poli; Cristina Panisi; Stefano Damiani; Francesco Barale; Pierluigi Politi
Journal:  J Autism Dev Disord       Date:  2016-03

9.  Inflammatory hydrocephalus.

Authors:  Stephanie M Robert; Benjamin C Reeves; Arnaud Marlier; Phan Q Duy; Tyrone DeSpenza; Adam Kundishora; Emre Kiziltug; Amrita Singh; Garrett Allington; Seth L Alper; Kristopher T Kahle
Journal:  Childs Nerv Syst       Date:  2021-06-23       Impact factor: 1.475

Review 10.  Inflammation in acquired hydrocephalus: pathogenic mechanisms and therapeutic targets.

Authors:  Jason K Karimy; Benjamin C Reeves; Eyiyemisi Damisah; Phan Q Duy; Prince Antwi; Wyatt David; Kevin Wang; Steven J Schiff; David D Limbrick; Seth L Alper; Benjamin C Warf; Maiken Nedergaard; J Marc Simard; Kristopher T Kahle
Journal:  Nat Rev Neurol       Date:  2020-03-09       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.